Asset Program

Ready-to-use, AI-Validated Drug Candidate Packages

The Asset Program represents a portfolio of pre-validated drug candidates verified through in silico screening and binding affinity assays. It mitigates early discovery-stage risks while ensuring a seamless pipeline from research and development through to commercialization.

Why Syntekabio Asset Program

Ready-to-Go Package

Ready-to-use drug candidate packages validated through proactive discovery and in silico verification

Eliminates early-stage exploration uncertainties and enables rapid R&D initiation.

From Research to Business

Seamless execution framework from research to commercialization

Supports the entire pipeline from PoC validation through collaborative research, follow-on development, and licensing-out.

Platform-Validated Quality

Consistent reproducibility and reliability verified through AI platform.

Derived from Syntekabio's proprietary AI platform and integrated analysis pipeline, it offers reliable criteria for subsequent research and development.

Asset Program List

No	Target Protein	Indications	Mechanism of Action	Marketed drugs / Pipeline Drugs
1	PD-L1 (CD274)	Solid tumors, lymphoma	PD-1/PD-L1 inhibition → T-cell activation	Atezolizumab, Durvalumab
2	PD-1 (PDCD1)	Solid tumors, hematologic malignancies	PD-1 inhibition → Immune checkpoint blockade	Pembrolizumab, Nivolumab
3	CTLA-4	Melanoma, renal cell carcinoma	Release of T-cell activation inhibition	Ipilimumab
4	LAG-3	Solid tumors, lymphoma	LAG-3 inhibition → Promotion of T-cell response	Relatlimab (Opdualag)
5	CD19	B-cell malignancies	Targeted elimination of B-cells	Blinatumomab, Tisagenlecleucel
6	CD20	Lymphoma, autoimmune diseases	Induction of B-cell depletion	Rituximab, Obinutuzumab
7	CD38	Multiple myeloma	Elimination of CD38-expressing cells	Daratumumab, Isatuximab
8	BCMA (TNFRSF17)	Multiple myeloma	Induction of BCMA-targeted cytotoxicity	Belantamab mafodotin, Teclistamab
9	Claudin 18.2 (CLDN18)	Gastric cancer, pancreatic cancer	Claudin 18.2 targeting	Zolbetuximab
10	Nectin-4 (PVRL4)	Urothelial cancer	Induction of Nectin-4 targeted cytotoxicity	Enfortumab vedotin
11	HER2 (ERBB2)	Breast cancer, gastric cancer	HER2 signaling inhibition, ADCC	Trastuzumab, Pertuzumab
12	HER3 (ERBB3)	HER2-mutated cancers	HER3 signaling inhibition	Patritumab deruxtecan
13	IL-4Ra (IL4RA)	Asthma, atopic dermatitis	Blockade of IL-4/IL-13 pathway	Dupilumab
14	IL-23p19 (IL23A)	Psoriasis, Crohn's disease	Inhibition of Th17 pathway	Guselkumab, Risankizumab
15	TNF-alpha	Autoimmune diseases (RA, CD, etc.)	Neutralization of inflammatory cytokine	Adalimumab, Infliximab
16	IL-12/IL-23 (040 subunit)	Psoriasis, Crohn's disease	Inhibition of IL-12/23 signaling	Ustekinumab
17	IL-1B	Autoinflammatory diseases	Blockade of inflammatory cytokine	Canakinumab
18	VEGF-A	Cancer, macular degeneration	Inhibition of angiogenesis	Bevacizumab, Ranibizumab
19	PCSK9	Dyslipidemia	Inhibition of LDL receptor degradation	Evolocumab, Alirocumab
20	ANGPTL3	Hyperlipidemia, NASH	Inhibition of lipid metabolism regulatory protein	Evinacumab
21	CGRP/CGRP-R	Migraine	Inhibition of CGRP signaling	Erenumab, Fremanezumab
22	FGFRIc / B-Klotho	Obesity, NASH	FGF21 pathway agonism	Bimagrumab, Pemvidutide

Asset Program Use Cases

Rapid Proof-Of-Concept (PoC) Validation

Deploy pre-validated candidates immediately to minimize development risks with minimal investment.

Enhanced Competitiveness in Collaborative Research And Proposals

Leverage AI-analyzed and validated candidates to strengthen competitiveness and enhance partnership success rates.

Rapid Expansion of New Targets And Pipelines

Accelerate portfolio expansion by incorporating pre-screened novel candidate packages from large-scale in silico screening into early-stage pipelines.

Syntekabio AI Platform Ensuring Asset Credibility

SM-ARS®

Rapidly derives high-quality, synthetically accessible candidates from a library of over 10 billion compounds using AI platforms.

AB-ARS®

Select optimal candidates by predicting antibody binding affinity and developability through AI-based automated CDR design.

DEEPMATCHER®

Predicts target-compound complex structures to select compounds with high molecular-model reliability.

LM-VS™

Predicts promising novel candidates with high development potential through AI screening based on target protein 3D structures.

FAQ

Looking for specific targets? Explore our portfolio of AI-based drug candidates and access detailed data now.

Contact UsContact Us